ChartRow logo
Data provided bySource: Twelve Data
TEVA
$42.61+1.99%
as of close, Nov 6, 2026
☾ AH $42.61 +1.99%
Teva Pharmaceutical Industries Limited American Depositary SharesStock · Healthcare
PeersHLNTAKVTRSZTSNBIXUTHR
Share this page

TEVA — Teva Pharmaceutical Industries Limited American Depositary Shares price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in TEVA be worth today? →
TEVA returns: By year · By month · By week · Trailing

Price data

Price
$42.61
YTD price return
+36.53%
YTD total return
+36.53%
Market cap
49.7B
Enterprise value
62.8B
Shares outstanding
1.2B
52W low
$23.61
52W high
$43.34
From 52W high
-1.68%
From 52W low
+80.47%
52W range
96%$23.61–$43.34
Beta
0.86

Volume

Rel volume
0.90×
30D volume
6.8M
30D $ vol
278.8M

Insider trading

Insider net 1W
−$3.0M
Insider net 1M
−$3.0M
Insider net 3M
−$18.7M
Insider net 1Y
−$96.2M

Form 4 transactions by trade date, as filed; latest on file 2026-11-05.

Fundamentals

Sales (ttm)
17.2B
Sales/share
$14.77
EPS (ttm)
$0.43
FCF (ttm)
1.2B
FCF/share
$1.06
Book value/share
$6.84
Net margin
2.94%
ROE
6.34%
ROA
1.26%
Debt / equity
1.59×
Current ratio
0.95

Growth (CAGR, ttm) · 10Y

Sales
+2.71%+4.10%+1.20%-2.43%
Net income
-28.95%n/a-6.97%+4.52%
FCF
+113.95%+26.67%+69.64%-8.66%
Shares
+1.70%+1.35%+1.13%+1.72%

Per-share growth (CAGR, ttm) · 10Y

EPS
-30.17%n/a-8.18%+20.49%
Sales/share
+0.99%+2.72%+0.07%-3.79%
FCF/share
+110.37%+24.99%+67.75%-9.93%
Book value/share
+8.22%+3.42%-6.34%-14.85%
Price
+74.27%+67.59%+36.07%+0.57%
Total return
+74.27%+67.59%+36.07%+0.95%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
98.9×
P/OI (ttm)
34.6×
Fwd P/E
13.4×
P/S (ttm)
2.9×
P/B (mrq)
6.2×
P/FCF (ttm)
40.2×
EV/EBITDA (fy)
25.9×
EV/Sales (ttm)
3.6×
FCF yield (ttm)
2.49%
Buyback yield (realized, 1y)
-1.70%
Shareholder yield (realized, 1y)
-1.70%
Buyback yield (cash, ttm)
0.00%
Shareholder yield (cash, ttm)
0.00%

Vs own 10Y history

P/OI
80th
P/S
100th
P/B
100th
P/FCF
90th

Bar = where today’s multiple sits in TEVA’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-06#

Data provided bySource: Twelve Data
1D
+1.99%
5D
+1.24%
1M
+8.89%
3M
+22.41%
YTD
+36.53%
1Y
+74.20%
5Y
+366.70%
1D
+1.99%
5D
+1.24%
1M
+8.89%
3M
+22.41%
YTD
+36.53%
1Y
+74.20%
5Y
+366.70%

Fundamentals#

Revenue

5Y CAGR +0.7%10Y CAGR −1.3%YoY −1.9%
$17.2B TTM$4.4B Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m10Y CAGR −4.3%YoY −19.0%
$1.4B TTM$714M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m10Y CAGR −4.0%YoY −45.9%
$0.43 TTM$0.20 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y CAGR +12.5%10Y CAGR −13.3%YoY −48.1%
$1.2B TTM$121M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow $1.8B, capex −$534M

Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow $241M, capex −$120M

Shares (diluted)

5Y +6.2%10Y +34.6%YoY +1.6%
1.2B TTM1.2B Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Dividend per share

5Y n/m10Y n/m
— FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Full TEVA financials →

About Teva Pharmaceutical Industries ADR#

Data provided bySource: Twelve Data

Teva Pharmaceutical Industries Ltd. ADR is a global pharmaceutical company focused on the development, production, and sale of medicines. Teva Pharmaceutical Industries Ltd. offers a broad portfolio that includes generic medicines, specialty branded treatments, over-the-counter products, active pharmaceutical ingredients, and contract manufacturing services. Its operations are organized across the United States, Europe, and International Markets, supporting distribution to healthcare systems, pharmacies, and patients in diverse regions. The company also provides out-licensing and other pharmaceutical services through affiliated platforms, making it an important supplier within the global drug manufacturing and distribution chain. Headquartered in Tel Aviv, Israel, Teva Pharmaceutical Industries Ltd. ADR plays a significant role in the access and supply of essential medicines across multiple therapeutic areas and market segments.

Tel Aviv-Yafo, Israel·31,173 employees·Drug Manufacturers - Specialty & Generic·tevapharm.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding TEVA#

4 of the 193 ETFs ChartRow carries live hold TEVA. Their positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Jul 26).

FundNameFiled weight
VEAVanguard FTSE Developed Markets ETF0.1%
VEUVanguard FTSE All-World ex-US ETF0.1%
VXUSVanguard Total International Stock ETF0.1%
VTVanguard Total World Stock ETF0.0%
TickerName1M1D
LLYEli Lilly and Company+16.98%-0.79%
JNJJohnson & Johnson+8.42%+1.43%
ABBVAbbVie Inc.+9.23%+1.07%
MRKMerck & Co. Inc.+3.37%-0.14%
UNHUnitedHealth Group Incorporated Common Stock (DE)+4.74%-0.40%
NVSNovartis AG+15.46%+0.38%
TMOThermo Fisher Scientific Inc.+5.81%+2.63%
AMGNAmgen Inc.+14.36%+0.03%